Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 638
Filtrar
Más filtros

Base de datos
Tipo del documento
Intervalo de año de publicación
1.
Endocr J ; 2024 Oct 24.
Artículo en Inglés | MEDLINE | ID: mdl-39443112

RESUMEN

There are differences in the responsiveness to differential diagnostic tests for Cushing's disease (CD), corticotroph tumor size, and the somatostatin receptor (SSTR) 5 expression in corticotroph tumors between CD patients. The differences in SSTR5 expression are particularly significant for identifying therapeutic targets for CD. However, prospective predictors of SSTR5 expression remain unclear. Thus, our objective was to elucidate the relationships among these clinical characteristics of CD, including SSTR5 expression. In 27 hospitalized patients with CD at Osaka University Hospital, Osaka, Japan, associations between corticotroph tumor diameter, the response of ACTH and cortisol to differential diagnostic tests for CD (CRH, desmopressin [DDAVP], and high-dose dexamethasone suppression test [HDDST]), the ACTH/cortisol index, and the SSTR5 immunoreactive score were retrospectively investigated. The response to differential diagnostic tests, ACTH/cortisol index, tumor diameter, and SSTR5 expression were significantly related (vs. tumor diameter [CRH: r = -0.54; DDAVP: r = -0.54; HDDST r = -0.67; ACTH/cortisol index: r = 0.76; SSTR5: r = -0.61], vs. CRH [DDAVP: r = 0.63, HDDST: r = 0.72, ACTH/cortisol index: r = -0.45; SSTR5: r = 0.56], vs. DDAVP [HDDST: r = 0.66; ACTH/cortisol index: r = -0.46; SSTR5: r = 0.76], vs. HDDST [ACTH/cortisol index: r = -0.62; SSTR5: r = 0.77], ACTH/cortisol index vs. SSTR5: r = -0.67). The areas under the receiver operating characteristic curve for the prediction of high SSTR5 expression via the CRH test, DDAVP test, HDDST, ACTH/cortisol index, and tumor diameter were 0.79, 0.87, 0.80, 0.71, and 0.71, respectively. Tests for differential diagnosis of CD, the ACTH/cortisol index, and the corticotroph tumor diameter have the potential for identifying SSTR5 expression in corticotroph tumors. These parameters may reflect the biological characteristics of corticotroph tumors.

2.
JCEM Case Rep ; 2(11): luae189, 2024 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-39430734

RESUMEN

Cortisol-producing adrenal adenomas consist of a mixture of lipid-rich clear and lipid-poor compact cells in varying proportions. Most adenomas are mainly composed of lipid-rich clear cells and typically exhibit low computed tomography (CT) attenuation values, high uptake on 131I-adosterol scintigraphy, and mild accumulation on 18F-fluorodeoxyglucose positron emission tomography/CT. However, adenomas predominantly composed of lipid-poor compact cells are rare, with limited evidence regarding their imaging characteristics. A 27-year-old woman with weight gain and a moon face was referred to our hospital. She presented with hypertension, dyslipidemia, low plasma ACTH levels, and autonomous cortisol secretion. We diagnosed this patient with ACTH-independent Cushing syndrome with a left adrenal tumor. The adrenal tumor exhibited imaging findings atypical for an adenoma, including high CT attenuation values, negative uptake on 131I-adosterol scintigraphy, and strong accumulation on 18F-fluorodeoxyglucose positron emission tomography/CT. Histopathological analysis indicated that the tumor was a rare type of adenoma, predominantly composed of lipid-poor compact cells. These findings and recent reports suggest that the proportion of compact cells can influence the imaging findings. Therefore, in the differential diagnosis, it is important to recognize that cortisol-producing adrenal adenomas predominantly composed of compact cells can present with atypical imaging findings.

3.
Case Rep Endocrinol ; 2024: 2524019, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39435032

RESUMEN

Myxedema coma is a rare life-threatening form of hypothyroidism that manifests as neuropsychiatric, metabolic, respiratory, and cardiovascular dysfunction. From 2010 to 2022, our hospital managed three cases of myxedema coma. While the overall characteristics of these cases were similar to those in previous reports, we noticed that all cases were negative for thyroid autoantibodies and an autopsy in one of the cases exhibited end-stage thyroiditis. During a systematic review of cases from 1999 to 2022, we also noticed that a significant proportion of myxedema coma was caused by seronegative primary hypothyroidism especially in Japan.

4.
J Atheroscler Thromb ; 2024 Oct 03.
Artículo en Inglés | MEDLINE | ID: mdl-39358230

RESUMEN

AIMS: The effect of uric acid (UA)-lowering therapy with xanthine oxidoreductase (XOR) inhibitors on the development of cardiovascular disease requires further investigation. This study aimed to evaluate the long-term effects of febuxostat on arterial stiffness, focusing on liver function. METHODS: The PRIZE study involved random assignment of patients with asymptomatic hyperuricemia to receive either add-on febuxostat treatment (febuxostat group) or non-pharmacological treatment (control group). Of the 514 participants, 23 and 14 patients in the febuxostat and control groups, respectively, underwent assessment of arterial stiffness using the cardio-ankle vascular index (CAVI). The participants in each group were further grouped on the basis of their baseline alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels (above or below the media value or 30 U/L). The primary endpoint was the change in the CAVI from baseline to 12 and 24 months. RESULTS: Overall, no significant differences were found between the control and febuxostat groups in the least-squares mean estimates of changes in CAVI at 24 months (mean between-group difference, -0.41 [95% CI, -1.05 to 0.23]; p=0.204). However, there were significant differences in participants with higher baseline ALT or AST levels above 30 U/L at 24 months (mean between-group difference, -1.12 [95% CI, -2.23 to -0.01]; p=0.048 for ALT ≥ 30 U/L and -1.08 [95% CI, -2.13 to -0.03]; p=0.044 for AST ≥ 30 U/L). CONCLUSIONS: Two-year treatment with febuxostat demonstrated a beneficial effect on CAVI in patients with hyperuricemia and liver dysfunction.

5.
Diabetes Obes Metab ; 26(10): 4684-4693, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-39143658

RESUMEN

AIM: To assess the direct effect of intensive glycaemic control on periodontal tissues in patients with diabetes mellitus. MATERIALS AND METHODS: Twenty-nine patients with type 2 diabetes were enrolled and hospitalized to receive a 2-week intensive glycaemic control regimen. We observed and analysed the systemic and oral disease indicators before and after treatment and clarified the indicators related to periodontal inflammation. RESULTS: A significant reduction in glycaemic and periodontal parameters, including glycated albumin levels and periodontal inflamed surface area (PISA), was observed after treatment. The changes in PISA per tooth, indicative of periodontal healing, exhibited a bimodal distribution; the patients were divided into two groups on this basis. Correlations were observed between the changes in PISA per tooth and fasting plasma glucose, acetoacetic acid, and beta-hydroxybutyrate levels in the PISA-improved group. Significantly lower levels of C-peptide, coefficient of variation of R-R interval, and ankle-brachial pressure index were observed before treatment in the PISA non-improved group. CONCLUSIONS: Glycaemic control treatment can effectively improve periodontitis in patients with type 2 diabetes, even in the absence of specific periodontal treatments. However, the periodontal responsiveness to glycaemic control treatment depends on the systemic condition of the patient.


Asunto(s)
Glucemia , Diabetes Mellitus Tipo 2 , Control Glucémico , Periodontitis , Humanos , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/sangre , Masculino , Femenino , Persona de Mediana Edad , Glucemia/metabolismo , Periodontitis/complicaciones , Periodontitis/sangre , Periodontitis/terapia , Anciano , Hemoglobina Glucada/metabolismo , Hemoglobina Glucada/análisis , Hipoglucemiantes/uso terapéutico , Productos Finales de Glicación Avanzada , Albúmina Sérica Glicada , Albúmina Sérica/análisis , Péptido C/sangre , Índice Tobillo Braquial , Susceptibilidad a Enfermedades
6.
Nat Cell Biol ; 26(9): 1558-1570, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39174742

RESUMEN

Cells release intraluminal vesicles in multivesicular bodies as exosomes to communicate with other cells. Although recent studies suggest an intimate link between exosome biogenesis and autophagy, the detailed mechanism is not fully understood. Here we employed comprehensive RNA interference screening for autophagy-related factors and discovered that Rubicon, a negative regulator of autophagy, is essential for exosome release. Rubicon recruits WIPI2d to endosomes to promote exosome biogenesis. Interactome analysis of WIPI2d identified the ESCRT components that are required for intraluminal vesicle formation. Notably, we found that Rubicon is required for an age-dependent increase of exosome release in mice. In addition, small RNA sequencing of serum exosomes revealed that Rubicon determines the fate of exosomal microRNAs associated with cellular senescence and longevity pathways. Taken together, our current results suggest that the Rubicon-WIPI axis functions as a key regulator of exosome biogenesis and is responsible for age-dependent changes in exosome quantity and quality.


Asunto(s)
Envejecimiento , Proteínas Relacionadas con la Autofagia , Complejos de Clasificación Endosomal Requeridos para el Transporte , Exosomas , MicroARNs , Exosomas/metabolismo , Exosomas/genética , Animales , MicroARNs/genética , MicroARNs/metabolismo , Humanos , Envejecimiento/metabolismo , Envejecimiento/genética , Complejos de Clasificación Endosomal Requeridos para el Transporte/metabolismo , Complejos de Clasificación Endosomal Requeridos para el Transporte/genética , Proteínas Relacionadas con la Autofagia/metabolismo , Proteínas Relacionadas con la Autofagia/genética , Autofagia , Ratones , Senescencia Celular , Ratones Endogámicos C57BL , Células HEK293 , Endosomas/metabolismo , Ratones Noqueados , Masculino
7.
Diabetol Int ; 15(3): 379-388, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-39101158

RESUMEN

Aims/Introduction: The aim of the study was to evaluate the effects of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, on circulating levels of hepatic enzymes, uric acid and hemoglobin levels in patients with type 2 diabetes mellitus (T2DM). Materials and methods: We evaluated longitudinal changes in circulating aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γ-GTP), uric acid, and hemoglobin levels in tofogliflozin (n = 169) and conventional treatment groups (n = 170) using data obtained from the UTOPIA trial, a randomized prospective study conducted to evaluate the efficacy of tofogliflozin in preventing atherosclerosis. Results: Within 104 weeks, tofogliflozin treatment, but not conventional treatment, significantly reduced AST, ALT, and γ-GTP levels. This reduction was significantly greater in the tofogliflozin group than in the conventional group. Stratified analysis showed that, in patients with obesity (defined as body mass index (BMI) ≥ 25.0 kg/m2), significant differences were observed in AST, ALT, and γ-GTP changes from baseline to 104 weeks between treatment groups. However, in patients without obesity, there were no significant differences in AST and γ-GTP changes from baseline to 104 weeks between treatment groups. Multivariable regression analysis showed that changes in BMI and HbA1c levels were independently associated with changes in AST, ALT, and γ-GTP levels. The reduction of uric acid and the increase of hemoglobin from baseline to 104 weeks were significantly greater in the tofogliflozin group than in the conventional group. Conclusions: The beneficial effects of tofogliflozin on circulating levels of hepatic enzymes, uric acid, and Hb lasted for 2 years in patients with T2DM. Clinical trial registration: UMIN000017607 (https://www.umin.ac.jp/icdr/index.html). Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-024-00693-x.

8.
Diabetol Int ; 15(3): 605-610, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-39101180

RESUMEN

Immune checkpoint inhibitor (ICI)-related type 1 diabetes is an immune-related adverse event (irAE), occurring in slightly less than 1% of patients undergoing ICI therapy. Most cases develop during ICI treatment, with occurrences long after discontinuation being extremely rare. A 76-year-old woman, with no history of glucose tolerance issues, was diagnosed with lung adenocarcinoma with pleural invasion and underwent chemotherapy, including atezolizumab, an anti-programmed death-ligand 1 antibody. This treatment was discontinued due to disease progression, although she continued with other chemotherapy regimens. Approximately 5.5 months (166 days) after her last atezolizumab dose, she developed diabetic ketoacidosis, fulfilling the diagnostic criteria for fulminant type 1 diabetes. Anti-glutamic acid decarboxylase antibodies were positive. The patient carried susceptibility human leukocyte antigen (HLA) haplotypes, which are associated with type 1 diabetes. To date, including our patient, only nine cases of ICI-related type 1 diabetes developed after ICI discontinuation have been precisely reported. Eight cases originated from East Asia, with six exhibiting fulminant type 1 diabetes, and seven tested negative for islet-related autoantibodies. The reported cases were independent of ICI types, cycle number, or HLA haplotypes. Median time from the last ICI administration to diabetes onset was 4 months (range: 2-7 months). Although reports of cases occurring after ICI discontinuation are currently limited, their frequency may increase with the wider use of ICIs and improved survival rates of patients post-treatment. Therefore, it is crucial to remain vigilant for the development of ICI-related type 1 diabetes, not only during ICI administration, but also long after discontinuation. Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-024-00719-4.

9.
Biochem Biophys Res Commun ; 732: 150403, 2024 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-39047402

RESUMEN

AIM AND OBJECTIVE: Our recent report showed that soluble T-cadherin promotes pancreatic beta-cell proliferation. However, how and where the secretion of soluble T-cadherin is regulated remain unclear. METHODS AND RESULTS: Soluble T-cadherin levels significantly increased in leptin receptor-deficient db/db mice with hypoinsulinaemia or in wild-type mice treated with insulin receptor blockade by S961. Similar results were observed in human subjects; Diabetic ketoacidosis patients at the time of hospitalization had increased plasma soluble T-cadherin levels, which decreased after insulin infusion therapy. Patients with recurrent ovarian cancer who were administered a phosphatidylinositol-3 kinase (PI3K)-alpha inhibitor (a new anticancer drug) had increased plasma soluble T-cadherin and plasma C-peptide levels. Endothelial cell-specific T-cadherin knockout mice, but not skeletal muscle- or cardiac muscle-specific T-cadherin knockout mice, showed a 26 % reduction in plasma soluble T-cadherin levels and a significant increase in blood glucose levels in streptozocin-induced diabetes. The secretion of soluble T-cadherin from human endothelial cells was approximately 20 % decreased by insulin and this decrease was canceled by blockade of insulin receptor/Akt signalling, not Erk signalling. CONCLUSION: We conclude that insulin regulates soluble T-cadherin levels and soluble T-cadherin secretion from endothelial cells is positively regulated by insulin/insulin receptor/Akt signalling.


Asunto(s)
Cadherinas , Insulina , Proteínas Proto-Oncogénicas c-akt , Transducción de Señal , Animales , Cadherinas/metabolismo , Humanos , Proteínas Proto-Oncogénicas c-akt/metabolismo , Insulina/metabolismo , Insulina/sangre , Ratones , Femenino , Ratones Noqueados , Fosfatidilinositol 3-Quinasas/metabolismo , Receptor de Insulina/metabolismo , Células Endoteliales/metabolismo , Células Endoteliales/efectos de los fármacos , Masculino , Células Endoteliales de la Vena Umbilical Humana/metabolismo , Receptores de Leptina/metabolismo , Receptores de Leptina/genética , Péptidos
10.
Pituitary ; 27(5): 527-536, 2024 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-38954291

RESUMEN

PURPOSE: We previously showed the clinical characteristics of acromegaly with a paradoxical growth hormone (GH) response to oral glucose or thyrotropin-releasing hormone. However, the clinical characteristics of acromegaly with an increased GH response to luteinizing hormone-releasing hormone (LHRH responders) remain unclear. The aim of the present study was to evaluate the clinical characteristics, especially gonadotroph-related characteristics of LHRH responders in acromegaly. METHODS: The clinical characteristics of 33 LHRH responders and 81 LHRH nonresponders were compared. RESULTS: No differences in age, sex or basal serum levels of GH, insulin-like growth factor-1 (IGF-1), and gonadotropin were observed between the two groups. Steroidogenic factor 1 (SF-1), gonadotropin-releasing hormone receptor (GnRHR), and LH expression was more frequently observed in LHRH responders (P < 0.05). In addition, a greater increased rate of GH after LHRH loading, and the proportion of GnRHR and gonadotropin expression was observed in pituitary tumor with SF-1 expression than that without the expression (P < 0.01). LHRH responders showed a greater GH decrease in the octreotide test and a greater IGF-1 decrease after first-generation somatostatin ligand than LHRH nonresponders (P < 0.05). Furthermore, the proportion of hypointense pituitary tumors on T2-weighted magnetic resonance imaging and tumors with densely granulated type was higher in LHRH responders than in LHRH nonresponders, respectively (P < 0.05). No difference between the two groups was observed in either somatostatin receptor 2 or 5 expression. CONCLUSIONS: The increased GH response to LHRH is associated with the gonadotroph-related characteristics. This response may reflect the biological characteristics of somatotroph tumors.


Asunto(s)
Acromegalia , Hormona Liberadora de Gonadotropina , Hormona de Crecimiento Humana , Factor I del Crecimiento Similar a la Insulina , Humanos , Acromegalia/metabolismo , Acromegalia/sangre , Acromegalia/patología , Femenino , Masculino , Hormona Liberadora de Gonadotropina/metabolismo , Persona de Mediana Edad , Adulto , Hormona de Crecimiento Humana/metabolismo , Hormona de Crecimiento Humana/sangre , Factor I del Crecimiento Similar a la Insulina/metabolismo , Hormona Luteinizante/sangre , Hormona Luteinizante/metabolismo , Receptores LHRH/metabolismo , Factor Esteroidogénico 1/metabolismo , Gonadotrofos/metabolismo , Gonadotrofos/patología , Anciano
11.
Islets ; 16(1): 2379650, 2024 Dec 31.
Artículo en Inglés | MEDLINE | ID: mdl-39028826

RESUMEN

Islet amyloid polypeptide (IAPP) is a factor that regulates food intake and is secreted from both pancreatic islets and insulinoma cells. Here, we aimed to evaluate IAPP immunohistochemically in islets or insulinoma cells in association with clinical characteristics. We recruited six insulinoma patients and six body mass index-matched control patients with pancreatic diseases other than insulinoma whose glucose tolerance was confirmed to be normal preoperatively. IAPP and IAPP-insulin double staining were performed on pancreatic surgical specimens. We observed that the IAPP staining level and percentage of IAPP-positive beta cells tended to be lower (p = 0.1699) in the islets of insulinoma patients than in those of control patients, which might represent a novel IAPP expression pattern under persistent hyperinsulinemia and hypoglycemia.


Asunto(s)
Insulinoma , Polipéptido Amiloide de los Islotes Pancreáticos , Islotes Pancreáticos , Neoplasias Pancreáticas , Insulinoma/metabolismo , Insulinoma/patología , Humanos , Masculino , Femenino , Polipéptido Amiloide de los Islotes Pancreáticos/metabolismo , Persona de Mediana Edad , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/patología , Islotes Pancreáticos/metabolismo , Islotes Pancreáticos/patología , Adulto , Anciano , Inmunohistoquímica , Insulina/metabolismo
12.
Endocr J ; 71(10): 965-971, 2024 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-38925989

RESUMEN

We previously reported that a high HbA1c level 3 months before vitrectomy for vitreous hemorrhage or a large preoperative decrease in the HbA1c level over 3 months tended to increase the risk of rebleeding in diabetic retinopathy patients evaluated between 2010 and 2014. Here, we aimed to confirm these results with an extended study period and an increased number of operated eyes. This study included 121 diabetic patients who were admitted to Osaka University Hospital between 2010 and 2019 and who underwent vitrectomy for vitreous hemorrhage. Binomial logistic regression analysis was performed with the presence of postoperative bleeding as the outcome. The present study showed that the duration of the operation was associated with rebleeding (odds ratio = 1.02, p = 0.0016). A high HbA1c level just before vitrectomy tended to be associated with the bleeding (odds ratio = 1.27, p = 0.05), while preoperative HbA1c changes were not associated with rebleeding. The results of this study suggest that a high preoperative HbA1c level just before vitrectomy, not a decrease in HbA1c levels, in addition to the duration of the operation may increase the risk of postoperative bleeding after vitrectomy in diabetic retinopathy patients.


Asunto(s)
Retinopatía Diabética , Hemoglobina Glucada , Hemorragia Posoperatoria , Vitrectomía , Hemorragia Vítrea , Humanos , Retinopatía Diabética/cirugía , Retinopatía Diabética/sangre , Vitrectomía/efectos adversos , Hemoglobina Glucada/análisis , Hemoglobina Glucada/metabolismo , Hemorragia Vítrea/cirugía , Hemorragia Vítrea/etiología , Femenino , Masculino , Persona de Mediana Edad , Hemorragia Posoperatoria/sangre , Hemorragia Posoperatoria/etiología , Anciano , Periodo Preoperatorio , Estudios Retrospectivos , Factores de Riesgo
13.
Endocr J ; 2024 Jun 26.
Artículo en Inglés | MEDLINE | ID: mdl-38925988

RESUMEN

Lipid metabolism includes lipogenesis, lipolysis, and cholesterol metabolism and it exerts a wide range of biological effects. We previously found novel roles of adipocyte oxidative stress in diet-induced obesity, adipocyte glucocorticoid receptor in Cushing syndrome, and ARMC5 in adrenocortical cells. Using genetically modified mice in which oxidative stress was eliminated or augmented specifically in adipose tissues, we have been able to elucidate that obesity-induced oxidative stress inhibited healthy adipose expansion and ameliorated insulin sensitivity. Using adipocyte-specific glucocorticoid receptor knockout mice, we found that glucocorticoids also inhibited healthy adipose expansion and decreased insulin sensitivity. This was partly due to the transcriptional upregulation of ATGL. We identified ARMC5 as a novel ubiquitin E3 ligase of full-length SREBF, a master regulator of lipid metabolism. In adrenocortical cells, ARMC5 suppresses SREBF2 activity, and loss of ARMC5 may lead to cholesterol accumulation and the development of primary bilateral macronodular adrenal hyperplasia.

14.
Life Sci Alliance ; 7(8)2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38876803

RESUMEN

A lack of social relationships is increasingly recognized as a type 2 diabetes (T2D) risk. To investigate the underlying mechanism, we used male KK mice, an inbred strain with spontaneous diabetes. Given the association between living alone and T2D risk in humans, we divided the non-diabetic mice into singly housed (KK-SH) and group-housed control mice. Around the onset of diabetes in KK-SH mice, we compared H3K27ac ChIP-Seq with RNA-Seq using pancreatic islets derived from each experimental group, revealing a positive correlation between single-housing-induced changes in H3K27ac and gene expression levels. In particular, single-housing-induced H3K27ac decreases revealed a significant association with islet cell functions and GWAS loci for T2D and related diseases, with significant enrichment of binding motifs for transcription factors representative of human diabetes. Although these H3K27ac regions were preferentially localized to a polymorphic genomic background, SNVs and indels did not cause sequence disruption of enriched transcription factor motifs in most of these elements. These results suggest alternative roles of genetic variants in environment-dependent epigenomic changes and provide insights into the complex mode of disease inheritance.


Asunto(s)
Diabetes Mellitus Tipo 2 , Epigenómica , Islotes Pancreáticos , Animales , Ratones , Diabetes Mellitus Tipo 2/genética , Diabetes Mellitus Tipo 2/metabolismo , Islotes Pancreáticos/metabolismo , Masculino , Epigenómica/métodos , Histonas/metabolismo , Polimorfismo de Nucleótido Simple , Epigénesis Genética/genética , Diabetes Mellitus Experimental/genética , Estudio de Asociación del Genoma Completo , Modelos Animales de Enfermedad , Ratones Endogámicos C57BL
15.
J Diabetes Res ; 2024: 5574968, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38800586

RESUMEN

Islet transplantation (ITx) is an established and safe alternative to pancreas transplantation for type 1 diabetes mellitus (T1DM) patients. However, most ITx recipients lose insulin independence by 3 years after ITx due to early graft loss, such that multiple donors are required to achieve insulin independence. In the present study, we investigated whether skeletal myoblast cells could be beneficial for promoting angiogenesis and maintaining the differentiated phenotypes of islets. In vitro experiments showed that the myoblast cells secreted angiogenesis-related cytokines (vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and stromal-derived factor-1α (SDF-1α)), contributed to maintenance of differentiated islet phenotypes, and enhanced islet cell insulin secretion capacity. To verify these findings in vivo, we transplanted islets alone or with myoblast cells under the kidney capsule of streptozotocin-induced diabetic mice. Compared with islets alone, the group bearing islets with myoblast cells had a significantly lower average blood glucose level. Histological examination revealed that transplants with islets plus myoblast cells were associated with a significantly larger insulin-positive area and significantly higher number of CD31-positive microvessels compared to islets alone. Furthermore, islets cotransplanted with myoblast cells showed JAK-STAT signaling activation. Our results suggest two possible mechanisms underlying enhancement of islet graft function with myoblast cells cotransplantation: "indirect effects" mediated by angiogenesis and "direct effects" of myoblast cells on islets via the JAK-STAT cascade. Overall, these findings suggest that skeletal myoblast cells enhance the function of transplanted islets, implying clinical potential for a novel ITx procedure involving myoblast cells for patients with diabetes.


Asunto(s)
Diabetes Mellitus Experimental , Insulina , Trasplante de Islotes Pancreáticos , Mioblastos Esqueléticos , Neovascularización Fisiológica , Animales , Trasplante de Islotes Pancreáticos/métodos , Diabetes Mellitus Experimental/metabolismo , Mioblastos Esqueléticos/trasplante , Mioblastos Esqueléticos/metabolismo , Ratones , Masculino , Insulina/metabolismo , Factor de Crecimiento de Hepatocito/metabolismo , Ratones Endogámicos C57BL , Factor A de Crecimiento Endotelial Vascular/metabolismo , Islotes Pancreáticos/metabolismo , Islotes Pancreáticos/irrigación sanguínea , Quimiocina CXCL12/metabolismo , Glucemia/metabolismo , Diabetes Mellitus Tipo 1/metabolismo , Diabetes Mellitus Tipo 1/fisiopatología , Diabetes Mellitus Tipo 1/cirugía , Transducción de Señal , Secreción de Insulina , Diferenciación Celular
16.
Endocr J ; 71(7): 705-711, 2024 Jul 12.
Artículo en Inglés | MEDLINE | ID: mdl-38735737

RESUMEN

At the beginning of 2020, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to epidemics worldwide. Obesity and visceral fat accumulation have been reported to be independent risk factors for severe COVID-19. Several reports have focused on the levels of adipocytokines/adipokines, including adiponectin (APN), which is exclusively secreted from adipocytes, although the importance of these factors in acute disease conditions remains unclear. Therefore, we investigated the relationship between serum adiponectin levels and COVID-19 severity. Patients with COVID-19 who were admitted to Sumitomo Hospital (Osaka, Japan) from May through October 2021 were included. A total of 107 patients were enrolled in this study. We obtained the anthropometric and clinical laboratory data of the patients at the time of admission and examined the associations between various parameters and COVID-19 severity. The mean period from onset to admission was 6.5 ± 2.8 days. We divided the patients into "non-severe" (mild, moderate-I and moderate-II) (n = 80) and "severe" (n = 27) groups. The "severe" patients were significantly older than "non-severe" patients. Additionally, no significant differences were observed in BMI, sex, or the period from onset to admission. The serum adiponectin levels of "severe" patients at the time of admission were significantly greater than those of "non-severe" patients even after adjusting for age, sex, and BMI. These results suggest that the serum APN levels at the time of admission can predict COVID-19 severity. However, further investigations on the changes in APN levels in acute diseases are needed.


Asunto(s)
Adiponectina , COVID-19 , Índice de Severidad de la Enfermedad , Humanos , COVID-19/sangre , COVID-19/epidemiología , COVID-19/complicaciones , COVID-19/diagnóstico , Adiponectina/sangre , Masculino , Femenino , Anciano , Persona de Mediana Edad , SARS-CoV-2 , Japón/epidemiología , Anciano de 80 o más Años , Adulto , Hospitalización , Índice de Masa Corporal
17.
J Atheroscler Thromb ; 2024 May 14.
Artículo en Inglés | MEDLINE | ID: mdl-38749716

RESUMEN

AIM: The present study aimed to determine whether decreased masticatory performance and tongue-lip motor function are associated with an increased incidence of adverse health events in patients with metabolic disease. METHODS: One thousand patients with metabolic diseases including diabetes, dyslipidemia, hypertension, and hyperuricemia were recruited. Masticatory performance was assessed using a gummy jelly test, wherein glucose elution from chewed gummy jelly was measured. The tongue-lip motor function was measured using repeatedly pronounced syllables per second. Their association with the incidence of adverse health events (a composite of all-cause death, cardiovascular disease, bone fracture, malignant neoplasm, pneumonia, and dementia) was investigated using the generalized propensity score (GPS) method. RESULTS: During a median follow-up period of 36.6 (interquartile range, 35.0-37.7) months, adverse health events were observed in 191 patients. The GPS adjusted dose-response function demonstrated that masticatory performance was inversely associated with the incidence of adverse health events. The 3-year incidence rate was 22.8% (95% confidence interval, 19.0-26.4%) for the lower quartile versus 13.6% (10.5-16.7%) for the upper quartile (P<0.001). Similarly, the tongue-lip motor function was inversely associated with the incidence of adverse health events, with a 3-year incidence rate of 23.6% (20.0-27.0%) for the lower quartile versus 13.2% (10.4-15.9%) for the upper quartile (P<0.001). CONCLUSIONS: Decreased masticatory performance and tongue-lip motor function were associated with an increased incidence of adverse health events in patients with metabolic disease.

18.
Diabetes ; 73(7): 1122-1126, 2024 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-38656942

RESUMEN

We aimed to clarify the relationship between intra- and periorgan fats, visceral fat, and subcutaneous fat. We used abdominal computed tomography to evaluate intra- and periorgan fat accumulations in the pancreas, liver, spleen, renal parenchyma, renal sinus, and skeletal muscle. The relationships between these fats, visceral fat, and subcutaneous fat were examined by using partial correlation and covariance analysis, adjusting for BMI. We found that visceral fat and all intra- and periorgan fat accumulations were positively correlated, whereas subcutaneous fat and accumulations of all intra- and periorgan fats and visceral fat were negatively correlated. Individuals with excessive visceral fat accumulation had significantly greater accumulations of fat in the pancreas, liver, renal sinus, and skeletal muscle than those without excessive visceral fat accumulation (P = 0.01, 0.006, 0.008, and 0.02, respectively). In conclusion, all intra- and periorgan fat accumulations show a positive correlation with visceral fat and a negative correlation with subcutaneous fat, independent of BMI.


Asunto(s)
Grasa Intraabdominal , Bazo , Grasa Subcutánea , Tomografía Computarizada por Rayos X , Humanos , Grasa Intraabdominal/metabolismo , Grasa Intraabdominal/diagnóstico por imagen , Grasa Subcutánea/metabolismo , Grasa Subcutánea/diagnóstico por imagen , Masculino , Femenino , Persona de Mediana Edad , Adulto , Bazo/metabolismo , Bazo/diagnóstico por imagen , Hígado/metabolismo , Hígado/diagnóstico por imagen , Páncreas/metabolismo , Páncreas/diagnóstico por imagen , Riñón/metabolismo , Riñón/diagnóstico por imagen , Índice de Masa Corporal , Músculo Esquelético/metabolismo , Músculo Esquelético/diagnóstico por imagen , Anciano
19.
J Diabetes Investig ; 15(7): 906-913, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38445817

RESUMEN

AIMS/INTRODUCTION: In 2021, the guidelines on gestational weight gain (GWG) were revised and increased by 2-3 kg in Japan. This study aimed to investigate whether the revised guidelines would increase the incidence of babies with excessive birth weight in mothers with diabetes. MATERIALS AND METHODS: This retrospective study included 369 deliveries of women with diabetes whose pre-pregnancy body mass index was below 30 kg/m2 between 1982 and 2021. The primary outcome measure was large for gestational age (LGA). We compared the incidence of LGA between women who gained weight within the previous guidelines and women who gained weight within the revised guidelines. We also compared the incidence of macrosomia, preeclampsia, small for gestational age (SGA), and low birth weight. RESULTS: The incidence of LGA was not significantly different between women who gained weight within the revised guidelines and those within the previous guidelines (34.6% [95% confidence interval 25.6-44.6%] for the revised guidelines vs 28.9% [21.6-37.1%] for the previous guidelines; P = 0.246). Neither was the incidence of macrosomia or preeclampsia significantly different (8.7% [4.0-15.8%] vs 5.6% [2.5-10.8%] and 5.8% [2.1-12.1%] vs 6.3% [2.9-11.7%]; P = 0.264 and 0.824, respectively), while women who gained weight within the revised guidelines had a lower incidence of SGA (1.9% [0.2-6.8%] vs 10.6% [6.0-16.8%]; P = 0.001) and low birth weight (1.0% [0.02-5.2%] vs 7.0% [3.4-12.6%]; P = 0.023). CONCLUSIONS: The revised GWG guidelines could be beneficial in women with diabetes in terms of delivering babies with appropriate birth weight.


Asunto(s)
Peso al Nacer , Ganancia de Peso Gestacional , Humanos , Femenino , Embarazo , Estudios Retrospectivos , Japón/epidemiología , Adulto , Recién Nacido , Macrosomía Fetal/epidemiología , Macrosomía Fetal/etiología , Incidencia , Diabetes Gestacional/epidemiología , Recién Nacido Pequeño para la Edad Gestacional , Embarazo en Diabéticas/epidemiología , Índice de Masa Corporal , Pueblos del Este de Asia
20.
J Diabetes Investig ; 15(7): 843-850, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38459768

RESUMEN

AIMS/INTRODUCTION: We aimed to evaluate factors that influence changes in blood low-density lipoprotein cholesterol (LDL-C) levels after treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors in Japanese patients with type 2 diabetes. MATERIALS AND METHODS: We retrospectively analyzed clinical data of outpatients newly initiated on SGLT2 inhibitors (n = 176) and other oral antidiabetic drugs (n = 227). The patients were classified into four subgroups according to statin administration and baseline LDL-C levels (<120 or ≥120 mg/dL). Clinical characteristics were compared among the subgroups. Multivariate analysis was carried out to identify factors contributing to changes in LDL-C. RESULTS: The median follow-up period was 13.0 weeks (range 11.9-14.1 weeks, min 8 weeks, maximum 16 weeks) in the SGLT2i group, and 12.0 weeks (range 10.0-14.0 weeks, min 8 weeks, maximum 16 weeks) in the control group. Both groups showed a significant decrease in LDL-C (SGLT2i group -3.8 ± 24.7 mg/dL, control group -3.4 ± 15.0 mg/dL). Multivariate regression analyses showed that in both groups, the change in LDL-C depended on statin use and baseline LDL-C levels. Stratified analyses showed that LDL-C level was significantly decreased in statin users with baseline LDL-C ≥120 mg/dL (from 148.9 ± 33.5 to 109.3 ± 17.9 mg/dL, P = 0.002), and significantly increased in statin non-users with baseline LDL-C <120 mg/dL (from 96.3 ± 27.3 to 104.7 ± 24.8 mg/dL, P = 0.002). These changes were more characteristic for SGLT2 inhibitors than for other oral antidiabetic drugs (P for interaction = 0.010 and <0.001, respectively). CONCLUSIONS: LDL-C levels and statin medication at baseline influence changes in LDL-C after SGLT2 inhibitors treatment in Japanese patients with type 2 diabetes.


Asunto(s)
LDL-Colesterol , Diabetes Mellitus Tipo 2 , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Humanos , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/sangre , Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico , Masculino , LDL-Colesterol/sangre , Femenino , Estudios Retrospectivos , Persona de Mediana Edad , Anciano , Japón/epidemiología , Hipoglucemiantes/uso terapéutico , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Estudios de Seguimiento , Biomarcadores/sangre , Glucemia/análisis , Pueblos del Este de Asia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA